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SUMMARY
The aim was to provide a translation into Italian with cross-cultural adaptation of the French FLARE-Rheuma-
toid Arthritis (RA) questionnaire, and to test its acceptability, feasibility, reliability and construct validity in a 
single-centre cohort study.
The French version of the FLARE-RA questionnaire was cross-culturally adapted and translated into Italian 
following an established forward–backward translation procedure, with independent translations and back-
translations. To validate the Italian version we tested the internal validity with Cronbach’s alpha, test-retest 
reliability with the intraclass correlation coefficient, agreement between assessments with Bland-Altman plots 
and construct validity with Spearman’s correlation coefficients. 
The questionnaire was tested on 283 consecutive RA outpatients (mean age 56.1±13.9 years, 226/283 females, 
median disease duration 12.6 years ranging from 0.2 to 70.6). For the global score (11 items) the Cronbach’s 
alpha coefficient was 0.94. The intraclass correlation coefficient was 0.87 (95% CI, 0.76-0.96). The correlation 
of FLARE-RA global score was 0.59 (95% CI, 0.50-0.66) with the Disease Activity Score on 28 joints, 0.63 
(95% CI, 0.55-0.71) with the Simplified Disease Activity Index, 0.77 (95% CI, 0.71-0.83) with the RA Impact 
of Disease and 0.67 (95% CI, 0.59-0.73) with the Health Assessment Questionnaire.
The Italian version of the FLARE-RA is feasible, brief and easy to administer. The translated and cross-cul-
tural adapted showed accordingly to be valid and reliable. This questionnaire has some practical advantages, 
such as clarity, comprehensiveness, simplicity, and a minimum filling time. The development of cross-cultural 
adapted questionnaires in different languages is of pivotal importance to obtain standardized and comparable 
data across countries.
Key words: Rheumatoid arthritis; self-administered questionnaire; patient reported outcome measures; flare; 
disease exacerbation.
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n	 INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease char-
acterized by joint swelling, pain and stiff-
ness leading to a gradual joint damage and 
a progressively increasing disability (1). 
The treat-to-target strategy has proven ef-
fective in achieving disease remission (2). 
However, a number of patients with RA do 
not reach remission, despite they receive 
the latest therapies.
A mounting body of evidence suggests that 
disease flares occur in more than half of 
the patients and contribute to radiographic 
damage and disease progression (3-6). It 
has been demonstrated that disease flares 
substantially contribute to patient burden, 
poorer health-related quality of life, dis-
ability, healthcare use and costs (6-10). 
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Although disease remission is an important 
endpoint in clinical trials, lack of consen-
sus on flare definition and measurement 
makes it challenging. Moreover, due to 
different cultural backgrounds or different 
perceptions of the disease, the concept of 
disease flare may vary between physicians 
and patients and among patients them-
selves (11, 12).
Over the last few years, increasing attention 
has been devoted to the patient-centered 
perspective of the disease by adopting dedi-
cated patient-reported outcomes (PROs) in 
clinical practice and research setting (13). 
The use of PROs to quantify disease flares 
promotes the inclusion of patient perception 
in the clinical assessment of RA in addition 
to the physician point of view. 
Recently, the self-administered Flare As-
sessment in Rheumatoid Arthritis (FLARE-
RA) questionnaire has been developed with 
a modern psychometric method, accounting 
for patient and physician perspectives in 
France, and it has been validated in French 
(14, 15). It focuses on episodes of flare re-
ported by patients, which occurred in the 
past 3 months or since the last clinic visit.
This study aims to provide a translation 
into Italian with a cross-cultural adaptation 
of the French FLARE-RA questionnaire. 
Moreover, we tested its acceptability, fea-
sibility, reliability and construct validity in 
a single-centre cohort study.
n	 MATERIALS AND METHODS
Study design
The study was designed to validate the Ital-
ian version of the FLARE-RA question-
naire according to COSMIN (Consensus-
based Standards for the Selection of Health 
Status Measurement Instruments) method-
ological standards (16, 17).
Cultural adaptation and translation
The French version of the FLARE-RA 
questionnaire was cross-culturally adapted 
and translated into Italian following the 
principles of good practice for the trans-
lation and cultural adaptation process for 
PROs (18). The translation followed an 
established forward–backward translation 
procedure, with independent translations 
and back-translations (19).
Patients
The study population consisted of all 
consecutive patients aged ≥18 years who 
met the 1987 American College of Rheu-
matology (ACR) (20) and/or 2010 ACR/
European League Against Rheumatism 
classification criteria (EULAR) (21) for 
RA referring to the in- and outpatient 
rheumatology clinic at ASST Pini-CTO in 
Milan (Italy). All patients had disease du-
ration ≥3 months, and the treatment with 
disease modifying anti-rheumatic drugs 
(DMARDs) was ongoing for at least 2 
months. Overlap syndrome patients (RA 
overlapping with systemic sclerosis, sys-
temic lupus erythematosus, mixed con-
nective tissue disease, Sjögren’s syn-
drome, dermatomyositis or polymyositis) 
were excluded. Moreover, RA patients 
who were unable to comply with protocol 
recommendations, including language is-
sues (i.e. reading, comprehension, speak-
ing, and use of Italian), were excluded.
Collected data
Demographic data, RA features, RA dis-
ease activity (DAS28-CRP - Disease Activ-
ity Score in 28 joints using C-reactive pro-
tein and SDAI - Simplified Disease Activ-
ity Index), ongoing RA treatment, patient’s 
and physician’s global health assessments 
(visual analog scale - VAS - from 0=best 
to 10=worst) were collected (22, 23). In 
particular, the ad-hoc forms included: date 
of birth, gender, weight, height, education, 
native language, region of residence, citi-
zenship, age at disease onset, erythrocyte 
sedimentation rate, CRP, positivity for 
rheumatoid factor and/or anti-citrullinated 
protein antibodies, presence of structural 
damage on radiographs (presence or ab-
sence of erosions), ongoing and past con-
ventional and biologic DMARDs, on-go-
ing symptomatic therapy (corticosteroids, 
non-steroidal anti-inflammatory drugs).
Moreover, patients were required to fill 
out the Health Assessment Questionnaire 
(HAQ) (24) and the Rheumatoid Arthritis 
Impact of Disease (RAID) scale (25).
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The Italian version of the FLARE-RA 
questionnaire was administered to all pa-
tients. Each statement was then graded by 
a patient on a numerical rating scale from 0 
(completely untrue) to 10 (absolutely true). 
The FLARE-RA questionnaire was then 
re-tested in a subset of patients in order to 
assess its reproducibility.
Statistical analysis
Distributions and missing data were evalu-
ated, and descriptive statistics were calcu-
lated. For each item, the subscales and the 
total score were calculated and floor and 
ceiling effects were evaluated based on the 
proportions of participants who gave the 
highest and lowest scores, respectively. 
The degree to which the questionnaire pro-
duced unidimensional scores was assessed 
by Cronbach’s alpha (internal consistency). 
For test-retest reliability, randomly selected 
stable patients were asked to complete the 
questionnaire again after the first adminis-
tration (this time frame was chosen to avoid 
memory bias). On the basis of the test-retest 
data, reliability was calculated using the in-
traclass correlation coefficient (ICC) from 
the two different times and a two-way mixed 
effects model was used. Agreement between 
the assessments was also explored visu-
ally by the use of Bland-Altman plots and 
the smallest detectable difference (=1.96× 
standard deviation of the mean difference 
between scores) was calculated.
To assess the construct validity, the degree 
to which scores from the questionnaire 
correlated with other disease activity as-
sessments and PROs (convergent validity) 
was studied by Spearman’s correlation co-
efficients. The internal consistency, intra-
observer variability and construct validity 
were assessed for the model based on 11 
items and the two subscales.
For the comparison between two mean 
scores of questionnaires from known 
groups of interest (patient’s self-identifica-
tion of current flaring status, and remission/
low versus moderate/high disease activity 
using DAS28-CRP) Cohen’s d was used as 
effect size. 
The sample size was determined with the 
aim of assessing the correlation between 
the disease activity measures and PROs. 
A correlation of 0.1 was considered to be 
negligible (null correlation) against the 
alternative correlation of 0.25 (difference 
0.15). The estimated sample size was 261 
for a one-sided one-sample correlation test 
with a type I error alpha=0.05 and a power 
of 80%.
Analyses were performed using StataCorp. 
2017, Stata Statistical Software Release 15 
(College Station, TX: StataCorp LLC); p 
values <0.05 were considered statistically 
significant.
n	 RESULTS
Translation and cultural adaptation
The translation and cultural adaptation 
were performed by three physicians (F.I., 
N.U. and T.S.), one professional translator 
who was not a physician (L.G.), one na-
tive French speaker fluent in Italian (B.C.) 
and one Italian patient representative flu-
ent in French (P.C.) (Figure 1). At first, the 
original French version was independently 
translated into Italian by N.U. and L.G. 
Then, the two Italian versions were inde-
pendently translated back by B.C. and P.C.. 
To ascertain if the back-translations were 
Figure 1 - The process of translation and cultural adaptation into Ital-
ian of the original French FLARE-RA questionnaire.
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Table I - The FLARE-RA self-administered questionnaire in Italian.
Questionario FLARE-RA (autosomministrato)
Informazioni prima della compilazione del questionario: questo questionario è stato creato in modo tale da essere 
compilato sia dal paziente sia dal medico che raccoglie le risposte alle domande.
Indichi in che misura nel corso degli ultimi tre mesi (o dopo l’ultima visita) secondo lei le affermazioni qui sotto 
riportate sono vere (per favore segni il numero più appropriato).
1. Ha notato la comparsa o il peggioramento della rigidità articolare mattutina per più giorni di seguito.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
2. Ha notato la comparsa o il peggioramento del dolore in una o più articolazioni per più giorni di seguito.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
3. Ha notato la comparsa o il peggioramento del gonfiore in una o più articolazioni per più giorni di seguito.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
4. Ha notato la comparsa o il peggioramento dei risvegli per più notti di seguito a causa  
del dolore dell’artrite.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
5. Pensa che l’artrite sia peggiorata in modo netto per più giorni di seguito.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
6. Ha aumentato l’assunzione di medicinali contro il dolore (analgesici o anti-infiammatori) per più giorni 
consecutivi (se non assume alcun farmaco contro il dolore, selezioni “Assolutamente falso”).
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
7. Ha aumentato la sua assunzione di cortisone per più giorni di seguito a causa della sua artrite  
(se non assume cortisone, selezioni “Assolutamente falso”).
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
8. Si è sentita/o molto stanca/o per più giorni di seguito a causa della sua artrite.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
9. È stata/o così limitata/o che non poteva “fare più niente” per più giorni di seguito  
a causa della sua artrite.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
10. Si è sentita/o più irritabile del solito per più giorni di seguito a causa della sua artrite.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
11. Si è sentita/o depressa/o per più giorni di seguito a causa della sua artrite.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
12. Ha avuto voglia di rinchiudersi in se stessa/o o di isolarsi per più giorni di seguito  
a causa della sua artrite.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
13. Ha provato un maggior bisogno di aiuto per più giorni di seguito a causa della sua artrite.
Assolutamente falso 0 1 2 3 4 5 6 7 8 9 10 Assolutamente vero
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nearly identical to the source document, 
F.G. cross-checked whether the two back-
translations matched the original French 
questionnaire. Finally, the two Italian ver-
sions were pooled to a common version. 
The pre-final Italian version was then pre-
tested on 5 patients with RA to ascertain 
that there were no problems with accept-
ance and comprehension of the question-
naire content or phrasing. The final version 
of the questionnaire is shown in Table I.
Feasibility, study population and 
FLARE-RA item statistics
Before starting the study, a debriefing on 
clarity of questions and time employed was 
conducted with 5 people with RA. Then, 
the study included 283 patients whose 
characteristics are shown in Table II. 
The descriptive statistics of the 13 items of 
the original FLARE-RA model are shown 
in Table III. Missing data for each item 
were very few (maximum 2.8% for the item 
on steroid intake increase) and only 2/283 
(0.7%) scores could not be calculated due to 
the excess of missing data as recommended 
by the developers (>2 missing items). The 
distributions of the items were right skewed 
and the lowest values were reported for the 
item on steroid intake increase since the 
rating 0 (i.e. the lack of steroid use) was 
reported by half of the patients (54.4%). 
Thus, the floor effect was maximal for this 
item, and lower than 40% for the other 
items. The ceiling effect was not substan-
tial (<10%) for any item. With regards to 
the FLARE-RA (sub)scales, the median 
(range) values of scores were 3.6 (0-10) for 
the 11-item global scale, 4.0 (0-10) for the 
5-item arthritis-related subscale, and 2.7 (0-
10) for the 6-item general subscale.
Internal consistency 
As in the original version, the calculation 
of the FLARE-RA score was based on an 
arithmetic mean of 11, 5, and 6 items for the 
global, arthritis-related, and general score, 
respectively, without any weighting. The 
Cronbach’s alpha coefficient for internal 
consistency was 0.94 for the global score, 
0.91 for the arthritis-related subscale, and 
0.93 for the general subscale. 
Table II - Characteristics of the 283 patients with Rheumatoid Arthritis includ-
ed in the study.
Demographics
Age, years, mean (sd) 56.1 (13.9)
Gender, female (%) 226/283 (79.9)
BMI, kg/m2, median (range) 23.6 (14.4 – 42.1)
Education, n (%)
 Primary school 34 (12.7)
 Secondary school 63 (23.6)
 High school 102 (38.2)
 University 68 (25.5)
Citizenship, Italian, n (%) 278/283 (98.2)^
Region of residence, Lombardy, n (%) 255/283 (90.1)§
RA features
Disease duration, years, median (range) 12.6 (0.25-70.6)
Serum ACPA+, n (%) 136/283 (48.1)
Serum RF+, n (%) 146/283 (51.6)
Erosive disease on X-ray, n (%) 123/218 (56.4)
RA disease activity
Swollen joint count, n, median (range) 0 (0 – 26)
Tender joint count, n, median (range) 0 (0 – 26)
Patient’s global assessment (0 – 10 VAS), mean (sd) 3.1 (2.0)
Physician’s global assessment (0 – 10 VAS), mean (sd) 2.4 (2.8)
ESR, mm/hour, median (range) 14 (0 – 104)
CRP, mg/liter, median (range) 1.5 (0 – 93)
DAS28-CRP, mean (sd) 2.4 (1.1)
 Remission (DAS28-CRP <2.4), n (%) 163/277 (58.8)
 Low Disease Activity (2.4<DAS28-CRP ≤2.9), n (%) 35/277 (12.6)
 Moderate Disease Activity (2.9<DAS28-CRP ≤4.6), n (%) 63/277 (22.7)
 High Disease Activity (DAS28-CRP >4.6), n (%) 16/277 (5.8)
SDAI score (0 – 86), mean (sd) 9.3 (10.0)
RAID score (0 – 10), mean (sd) 3.1 (2.6)
HAQ score (0 – 3), mean (sd) 0.58 (0.66)
Ongoing RA treatment
Steroids, n (%) 128/283 (45.2)
Prednisone equivalent dose, mg per day, mean (sd) 4.6 (2.4)
NSAIDs, n (%) 60/283 (21.2)
Conventional synthetic DMARD monotherapy, n (%) 108/283 (38.2)
Conventional synthetic DMARD combined with biologic 
DMARD, n (%) 74/283 (26.1)
Biologic DMARD monotherapy, n (%) 69/283 (24.4)
^non-Italian: 1 Bosnia, 1 Croatia, 1 Peru, 2 Romania; §extra-Lombardy: 13 north-
ern Italy, 3 central Italy, 12 southern Italy; sd: standard deviation; n: number; 
BMI: body mass index; RA: Rheumatoid Arthritis; ACPA: anti-citrullinated pro-
tein antibody; RF: rheumatoid factor; VAS: visual analogue scale; ESR: erythro-
cyte sedimentation rate; CRP: C-reactive protein; DAS28-CRP: Disease Activity 
Score in 28 joints using C-reactive protein; SDAI: Simplified Disease Activity 
Index; RAID: Rheumatoid Arthritis Impact of Disease; HAQ: Health Assess-
ment Questionnaire; NSAIDs: non-steroidal anti-inflammatory drugs; DMARD: 
disease-modifying antirheumatic drug.
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Reliability
Fifteen patients repeated the questionnaire 
in two times (14±7 days after the first ad-
ministration). The ICC was excellent with 
0.87 (95% confidence interval - CI 0.76-
0.96), 0.77 (95% CI 0.63-0.92), and 0.79 
(95% CI 0.66-0.93) for the global, arthri-
tis-related, and general subscales, respec-
tively. The Bland-Altman plot for the total 
score showed 1/15 points (6.7%) outside 
the confidence interval; the mean (standard 
deviation) difference between the 2 meas-
ures was 0.24 (1.0), for a smallest detect-
able difference of 1.0.
Construct validity
The FLARE-RA total score and the 2 sub-
domain scores showed high correlation 
with the 6 outcome measures collected at 
the same time as the FLARE-RA question-
naire (Table IV). The strength of correla-
tion between FLARE-RA scores and the 
DAS28-CRP was moderate in the whole 
population and in the subgroup of patients 
with moderate/high disease activity (rho 
0.51-0.59, and 0.54-0.60), yet it was low in 
the subgroup which had low disease activ-
ity or a remission (rho 0.36-0.40). Similar 
coefficients were observed when SDAI 
was considered. The correlation was sub-
stantially high with RAID which evaluated 
the disease impact: it showed a moderate to 
high correlation both in the whole and in 
the stratified population according to dis-
ease activity (rho 0.68-0.77). The correla-
tion was moderate with HAQ, which was 
used to explore functional limitations (i.e. 
disease activity and disease-related irre-
versible damage). Moreover, FLARE-RA 
showed a moderate correlation with pa-
tient’s global assessment, but a low to neg-
ligible correlation was identified with the 
physician’s global assessment (Table IV).
Finally, the mean scores of the FLARE-RA 
questionnaires were higher in those pa-
tients who identified themselves as having 
a flare compared to those patients who did 
not with large effect sizes (Table V). When 
Table III - Distributions of the 13 items and the FLARE-RA global and subscale scores at baseline.
Item Mean (sd) Median (range) Floor effect, n (%) Ceiling effect, n (%)
Domain
1. Stiffness 4.4 (3.2) 4 (0-10) 50/281 (17.8) 25/281 (8.9)
2. Sleep 3.6 (3.2) 2 (0-10) 75/281 (26.7) 20/281 (7.1)
3. Swelling 4.5 (3.2) 4 (0-10) 53/282 (18.8) 22/282 (7.8)
4. Pain 5.1 (3.2) 6 (0-10) 41/281 (14.5) 27/281 (9.5)
5. Overall 3.5 (3.0) 2 (0-10) 71/280 (25.4) 18/280 (6.4)
6. Analgesics 3.2 (3.4) 2 (0-10) 111/281 (39.5) 16/281 (5.7)
7. Steroid 2.1 (3.1) 0 (0-10) 154/275 (56.0) 16/275 (5.8)
8. Fatigue 4.6 (3.1) 6 (0-10) 48/281 (17.1) 21/281 (7.5)
9. Limit 2.7 (2.7) 2 (0-10) 92/281 (32.7) 10/281 (3.6)
10. Irritability 3.7 (3.1) 2 (0-10) 65/283 (23.0) 19/283 (6.7)
11. Mood 3.4 (3.0) 2 (0-10) 74/283 (26.1) 15/283 (5.3)
12. Withdrawal 2.8 (2.9) 2 (0-10) 92/283 (32.5) 14/283 (4.9)
13. Help 3.2 (3.1) 2 (0-10) 80/282 (28.4) 16/282 (5.7)
FLARE-RA
Global scale (11 items*) 3.7 (2.4) 3.6 (0-10) 18/281 (6.4) 1/281 (0.3)
Arthritis subscale (5 items^) 4.1 (2.7) 4.0 (0-10) 26/282 (9.2) 3/282 (1.1)
General symptoms subscale (6 items§) 3.4 (2.6) 2.7 (0-10) 35/282 (12.4) 3/282 (1.1)
*Excluded items: 5. overall, 7. Steroid; ^Included items: 1. stiffness, 2. sleep, 3. swelling, 4. pain, 6. Analgesics; §Included items: 
8. fatigue, 9. limit, 10. irritability, 11. mood, 12. withdrawal, 13. help; n: number; sd: standard deviation; RA, rheumatoid arthritis.
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stratification for disease activity was con-
sidered (DAS28-CRP: remission/low vs 
moderate/high), significant differences in 
FLARE-RA scores were observed for total 
and subscales.
n	 DISCUSSION  
AND CONCLUSIONS
Our results showed that the Italian version of 
FLARE-RA has a good degree of construct 
validity, with unidimensional scores (con-
sistent), and proved to be a reliable instru-
ment to measure disease flares in patients 
with RA; namely, the Italian version showed 
similar results as compared to the French 
version concerning internal consistency, re-
producibility and convergent validity.
The Italian and the French cohort (15) were 
similar by age and gender distribution. By 
contrast, in the French cohort (n=138) 
more patients with an aggressive RA sub-
set (i.e. anti-citrullinated protein antibod-
ies, rheumatoid factor, erosions on X-ray, 
HAQ) were included compared to the Ital-
ian cohort (n=283). As expected in our co-
hort, the percentage of remission was high-
er (59% vs. 41%) and fewer patients were 
treated with biologics. In our study DAS28 
was calculated considering CRP, whereas 
in the French version ESR was used.
The measurement properties of the ques-
tionnaire were comparable in the two co-
horts. Particularly, this study showed that 
the FLARE-RA questionnaire had excel-
lent feasibility and reliability, and high 
Table IV - Correlations of FLARE-RA total scores and subscales with measures of disease activity, disease impact, functional limita-
tions, and patient’s and physician’s global assessments.
Global scale
(11 items)
rho (CI)
Arthritis 
Subscale (5 items)
rho (CI)
General symptoms
Subscale (6 items)
rho (CI)
Whole population, n=277
DAS28-CRP 0.59 (0.50-0.66) 0.59 (0.50-0.66) 0.51 (0.42-0.60)
SDAI 0.63 (0.55-0.71) 0.64 (0.55-0.71) 0.55 (0.46-0.64)
RAID 0.77 (0.71-0.83) 0.68 (0.60-0.74) 0.75 (0.68-0.80)
HAQ 0.67 (0.59-0.73) 0.58 (0.49-0.66) 0.66 (0.58-0.73)
Patient’s global (0 - 10 VAS) 0.69 (0.63-0.75) 0.63 (0.55-0.70) 0.67 (0.60-0.73)
Physician’s global (0 - 10 VAS) 0.44 (0.34-0.54) 0.46 (0.37-0.55) 0.36 (0.26-0.47)
Patients in Remission / Low Disease Activity, n=198 
DAS28-CRP 0.40 (0.27-0.51) 0.36 (0.23-0.49) 0.37 (0.23-0.48)
SDAI 0.51 (0.39-0.61) 0.48 (0.37-0.59) 0.45 (0.33-0.57)
RAID 0.71 (0.61-0.78) 0.59 (0.47-0.68) 0.71 (0.63-0.78)
HAQ 0.58 (0.48-0.69) 0.46 (0.33-0.57) 0.59 (0.49-0.68)
Patient’s global (0 - 10 VAS) 0.63 (0.55-0.71) 0.54 (0.42-0.62) 0.62 (0.54-0.70)
Physician’s global (0 - 10 VAS) 0.25 (0.11-0.38) 0.30 (0.15-0.41) 0.17 (0.03-0.30)
Patients in Moderate / High Disease Activity, n=79
DAS28-CRP 0.60 (0.43-0.72) 0.57 (0.42-0.70) 0.54 (0.34-0.70)
SDAI 0.52 (0.34-0.67) 0.53 (0.35-0.67) 0.45 (0.26-0.63)
RAID 0.71 (0.56-0.83) 0.58 (0.38-0.73) 0.73 (0.59-0.83)
HAQ 0.63 (0.46-0.76) 0.53 (0.31-0.68) 0.65 (0.47-0.79)
Patient’s global (0 - 10 VAS) 0.58 (0.35-0.73) 0.54 (0.35-0.70) 0.56 (0.33-0.72)
Physician’s global (0 - 10 VAS) 0.25 (0.04-0.44) 0.26 (0.05-0.45) 0.21 (-0.02-0.43)
Correlation coefficients are reported as Spearman’s rho. CI: bootstrap Confidence Intervals based on 1000 bootstrap resamples with 
bias-corrected method. DAS28-CRP: Disease Activity Score in 28 joints using C-reactive protein; SDAI: Simplified Disease Activity 
Index; RAID: Rheumatoid Arthritis Impact of Disease; HAQ: Health Assessment Questionnaire; VAS: visual analogue scale; n: number.
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convergent validity with other indices of 
disease activity (DAS28-CRP, HAQ, and 
RAID scores) measured at the same time. 
The highest correlation was found be-
tween the FLARE-RA questionnaire and 
RAID. This finding is consistent with the 
patient-derived composite nature of the the 
RAID score which assesses the seven most 
important domains of impact of RA (25). 
Then, the FLARE-RA did correlate well 
with DAS28-CRP, particularly in patients 
with moderate/high disease activity. In the 
Italian cohort, the convergence between 
FLARE-RA and SDAI was studied for the 
first time and a moderate correlation was 
observed both in the whole population and 
when stratification by disease activity was 
considered. These results are comparable 
with DAS28-CRP and consistent with the 
known degree of agreement between SDAI 
and DAS28-CRP scores in clinical practice 
(26). A moderate correlation with HAQ 
was observed in the Italian cohort as well 
as in the French one and this finding is con-
sistent with the association of HAQ score 
with flares in RA patients (27). 
Table V - FLARE-RA scores by flare status using 2 patient-reported definitions of flare (presence with and 
without quantification of severity and duration) and by disease activity score in 28 joint.
Definition
FLARE-RA Effect 
Size§mean (sd) mean difference (CI 95%)
Patient reported flare Flare
+ –
Global scale
Presence*
n=83
5.7 (2.3)
n=198
2.9 (2.0) 2.8 (2.2-3.4) 1.23
Presence + severity + duration**
n=59
6.2 (2.2)
n=222
3.1 (2.1) 3.1 (2.5-3.8) 1.22
Arthritis subscale
 
Presence*
n= 83
6.5 (2.3)
n=198
3.2 (2.3) 3.3 (2.7-3.9) 1.32
 
Presence + severity + duration**
n=59
7.0 (2.1)
n=222
3.4 (2.4) 3.6 (2.9-4.2) 1.26
General symptoms subscale
 
Presence*
n=83
5.1 (2.7)
n=19
2.7 (2.1) 2.4 (1.8-3.1) 0.95
 
Presence + severity + duration**
n=59
5.7 (2.8)
n=222
2.8 (2.2) 2.8 (2.0-3.5) 0.98
DAS28-CRP
Disease Activity
Moderate/High Remission/Low
Global scale
n=79
5.5 (2.2)
n=198
3.0 (2.1) 2.5 (2.0-3.1) 1.06
Arthritis subscale
n=79
6.2 (2.3)
n=198
3.2 (2.4) 2.3 (2.4-3.6) 1.13
General symptoms subscale
n=79
4.9 (2.6)
n=198
2.7 (2.3) 2.2 (1.5-2.8) 0.84
§Cohen d statistic. *Patients answered “yes” to the question “Are you having a flare at this time?”; 
** Patient reported flare AND patient-rated severity >4/10 AND reported duration >7 days. DAS28-CRP: 
Disease Activity Score in 28 joints using C-reactive protein; CI: confidence interval.
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Our study has some limitations. First, the 
disease flare is related to a change of the 
disease activity over time (past 3 months 
or since the last clinic visit) and the con-
vergent validity was studied with current 
disease activity assessment. However, the 
effect sizes were large, when the FLARE-
RA scores were compared between groups 
with two different patient self-definitions 
of flare. Secondly, this cohort was from a 
monocentric study from northern Italy and 
geographical specificities could have been 
marginally taken into account, although 
these differences may be negligible.
In conclusion, the incorporation of validated 
RA measures like FLARE-RA to identify 
the disease flare into a practice’s workflow 
is expected to facilitate the adherence to the 
ACR/EULAR guidelines for the treatment 
of RA, which include concepts of treat-to-
target and tight control. The development 
and validation of multiple-language ver-
sions of existing validated questionnaires 
play a key role in standardizing the outcome 
measures collected in trials and prospective 
cohort studies. The Italian version of the 
FLARE-RA is feasible since it is brief and 
easy to administer, and appears to be valid 
and reliable now also in Italian. In addition, 
this questionnaire has some practical advan-
tages such as clarity, comprehensiveness, 
simplicity, and minimum filling time.
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